AFP and End Stage Liver Disease: In the setting of LT, the TBS has been included in models such as the Hazard Associated with Liver Transplantation for Hepatocellular Carcinoma (HALT–HCC) to predict overall survival outcomes in combination with clinically relevant variables such as model for end-stage liver disease-sodium (MELD–Na), alpha-fetoprotein (AFP), year of transplantation, underlying cause of cirrhosis, neutrophil–lymphocyte ratio, history of locoregional therapy, and Milan criteria status [20].